Cited 0 times in Scipus Cited Count

Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model

Authors
Koh, J | Kim, S | Lee, SN | Kim, SY | Kim, JE | Lee, KY | Kim, MS | Heo, JY | Park, YM | Ku, BM | Sun, JM | Lee, SH | Ahn, JS | Park, K | Yang, S  | Ha, SJ | Lim, YT | Ahn, MJ
Citation
Nanomedicine : nanotechnology, biology, and medicine, 37. : 102415-102415, 2021
Journal Title
Nanomedicine : nanotechnology, biology, and medicine
ISSN
1549-96341549-9642
Abstract
Although immune checkpoint inhibitors have significantly improved clinical outcomes in various malignant cancers, only a small proportion of patients reap benefits, likely due to the low number of T cells and high number of immunosuppressive cells in the tumor microenvironment (TME) of patients with advanced disease. We developed a cancer vaccine adjuvanted with nanoemulsion (NE) loaded with TLR7/8 agonist (R848) and analyzed its therapeutic effect alone or in combination with immune checkpoint inhibitors, on antitumor immune responses and the reprogramming of suppressive immune cells in the TME. NE (R848) demonstrated robust local and systemic antitumor immune responses in both subcutaneous and orthotopic mouse lung cancer models, inducing tumor-specific T cell activation and mitigating T cell exhaustion. Combination with anti-PD-1 antibodies showed synergistic effects with respect to therapeutic efficacy and survival rate. Thus, NE (R848)-based cancer vaccines could prevent tumor recurrence and prolong survival by activating antitumor immunity and reprogramming immunosuppression.
Keywords

MeSH

DOI
10.1016/j.nano.2021.102415
PMID
34174421
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pharmacology
Ajou Authors
양, 시영
Files in This Item:
There are no files associated with this item.
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse